Ciprofloxacin (CAS No.: 85721-33-1) - Broad-Spectrum Fluoroquinolone Antibacterial for Systemic & Local Infections

As a professional supplier of pharmaceutical-grade antibacterial active ingredients, we provide high-purity Ciprofloxacin that strictly complies with global pharmacopoeia standards (USP, EP, BP, CP). A second-generation fluoroquinolone, it exhibits potent bactericidal activity against a wide range of Gram-negative and Gram-positive bacteria, including many multidrug-resistant strains. It is widely used in human medicine for treating systemic and localized infections, and in veterinary practice for managing bacterial diseases in livestock and aquaculture-making it a cornerstone of modern antibacterial therapy.

Product Basic Information

Core Functions & Applications

Ciprofloxacin exerts its bactericidal effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV-enzymes critical for bacterial DNA replication, transcription, and repair. Its activity is concentration-dependent, with a post-antibiotic effect (PAE) that suppresses bacterial regrowth after drug levels decline. It demonstrates broad-spectrum activity, particularly against Gram-negative bacteria (e.g., Escherichia coli, Pseudomonas aeruginosa) and select Gram-positive pathogens (e.g., Staphylococcus aureus). It is used in both human medicine and veterinary practice:

1. Human Pharmaceutical Field

1.1 Urinary Tract Infections (UTIs)

Uncomplicated UTIs: First-line treatment for cystitis caused by E. coli (the most common UTI pathogen). Oral dose: 250-500 mg twice daily for 3-7 days, with cure rates exceeding 90%.

Complicated UTIs & Pyelonephritis: Treats severe infections (e.g., kidney infections) caused by multidrug-resistant E. coli or Klebsiella pneumoniae. IV infusion (400 mg every 12 hours) initially, followed by oral maintenance (500-750 mg twice daily) for 7-14 days.

1.2 Respiratory Tract Infections

Hospital-Acquired Pneumonia (HAP): Used for HAP caused by Gram-negative pathogens (e.g., Pseudomonas aeruginosa, Enterobacter spp.) or methicillin-sensitive S. aureus (MSSA). IV dose: 400 mg every 8-12 hours for 7-14 days, adjusted for renal function.

Acute Bacterial Sinusitis: Treats infections unresponsive to β-lactams, caused by Haemophilus influenzae or Moraxella catarrhalis. Oral dose: 500 mg twice daily for 10-14 days.

1.3 Other Infections

Skin & Soft Tissue Infections: Effective for cellulitis, abscesses, and wound infections caused by S. aureus (MSSA) or Pseudomonas aeruginosa. Oral/IV dose: 500-750 mg twice daily for 7-14 days.

Gastrointestinal Infections: Treats traveler's diarrhea (caused by enterotoxigenic E. coli) and shigellosis (caused by Shigella spp.). Oral dose: 500 mg twice daily for 3-5 days, reducing symptom duration by 50%.

Anthrax Post-Exposure Prophylaxis: Recommended by CDC for preventing anthrax after exposure to Bacillus anthracis. Oral dose: 500 mg twice daily for 60 days.

2. Veterinary Field

2.1 Livestock & Poultry

Respiratory Infections:

Bovine respiratory disease (BRD) in cattle (caused by Mannheimia haemolytica, Pasteurella multocida): Injectable solution (2.5-5 mg/kg body weight, once daily for 3-5 days) or oral premixes.

Avian colibacillosis in poultry (caused by E. coli): Soluble powders (50-100 mg/kg feed) for 3-5 days, reducing mortality in flock outbreaks.

Urinary & Gastrointestinal Infections:

Porcine cystitis (caused by E. coli) and swine salmonellosis: Oral dose (10-15 mg/kg body weight daily) for 5-7 days, improving feed conversion and reducing shedding of pathogens.

2.2 Aquaculture

Bacterial Diseases in Fish & Shrimp:

Vibriosis in marine fish (e.g., salmon, sea bass) caused by Vibrio anguillarum: Administered via feed (10-20 mg/kg body weight daily) for 5-7 days, controlling mortality in aquaculture ponds.

Aeromoniasis in freshwater fish (e.g., catfish, tilapia) caused by Aeromonas hydrophila: Bath treatments (5-10 mg/L water) or feed additives, preventing skin ulcers and septicemia.

Quality & Safety Assurance

Ciprofloxacin's widespread use demands rigorous quality control to ensure efficacy, minimize resistance, and ensure safety in both humans and food-producing animals:

Raw Material & Synthesis: Produced via multi-step chemical synthesis (cyclization of fluoroquinolone intermediates) followed by purification via recrystallization. Raw materials meet USP/EP standards for impurity limits (e.g., desethylene ciprofloxacin ≤0.3%, a major degradation product).

Production Process:

Pharmaceutical Grade: Manufactured in GMP-certified workshops (Class C cleanroom for injectable-grade raw materials) with strict control over pH and temperature to prevent racemization.

Veterinary Grade: Undergoes additional testing for aquatic safety (e.g., no toxic residues harmful to non-target organisms) and complies with veterinary pharmacopoeia standards.

Comprehensive Testing Protocol:

Safety Reminders:Human Use:

Contraindications: Hypersensitivity to fluoroquinolones; children <18 years (risk of articular cartilage damage); pregnancy/lactation (Category C-potential fetal risk).

Adverse Effects: Gastrointestinal upset, headache, dizziness, and rare but serious tendon rupture (especially in elderly or those taking corticosteroids). Avoid excessive sun exposure (photosensitivity risk).

Veterinary Use:

Withdrawal Periods: Cattle: 14 days (meat), 48 hours (milk); Pigs: 5 days (meat); Fish: 300-500 degree-days (calculated by water temperature × days).

Resistance Warning: Restrict use in food animals to avoid cross-resistance with human pathogens (e.g., E. coli, Salmonella).

Cooperation & Contact

We supply Ciprofloxacin in multiple grades and formulations to meet diverse needs:

Pharmaceutical Grade: Raw powder for oral tablets, capsules, IV injections, and ophthalmic solutions (1kg-100kg per order).

Veterinary Grade: Raw powder for injectables, premixes, and aquaculture formulations (10kg-500kg per order; monthly production capacity of 1000kg).

Value-added services include:

Providing DMF (Drug Master File) and CEP (Certificate of Suitability) for pharmaceutical-grade products to support registration in the EU, US, and Asia.

Customized formulation support (e.g., solubility enhancement for oral suspensions, stable injectable solutions for livestock).

Technical guidance on resistance management (veterinary clients) and dosage adjustments for renal impairment (human health clients).

If you are a pharmaceutical manufacturer, veterinary drug enterprise, or aquaculture supplier, please contact us for detailed cooperation:

Contact Information:

Email: sales@huarongpharma.com

Phone/WhatsApp: +86 13751168070

We adhere to the principles of "quality compliance, responsible use, and long-term partnership" and look forward to supporting global healthcare and animal health initiatives!

Hot Tags: Ciprofloxacin 85721-33-1, Pharmaceutical Grade Ciprofloxacin, Fluoroquinolone Antibacterial, UTI Treatment, Veterinary Antibacterial, Aquaculture Antibiotic, China Ciprofloxacin Supplier

Hot Tags: ciprofloxacin cas#85721-33-1, China ciprofloxacin cas#85721-33-1 manufacturers, suppliers, api for food and beverage, api for fraud detection, api for hospital information systems, api for influencer marketing, api for outbound marketing, enterprise api